MASLD风险分层、治疗启动与应答监测的更新全球共识建议
对非肝硬化且LSM 10-20 kPa或ELF 9.2-11.3者考虑resmetirom或semaglutide,不推荐两药 upfront 联合,1年应答定义为LSM下降≥30%或ELF下降≥0.5分。
要点
- FIB-4为首选初筛,VCTE或ELF用于二次分层。
- 非肝硬化、LSM 10-20 kPa或ELF 9.2-11.3可考虑resmetirom或semaglutide。
- 不推荐两药 upfront 联合;1年应答为LSM降≥30%或ELF降≥0.5分。
核心结论
- 更新共识提供整合常用无创检测与近期获批药物的实用算法,支持基于风险的分层诊疗标准化。
研究设计与样本
- 采用结构化Delphi流程,基于2025年1月至11月系统更新文献回顾,40位国际专家(肝病、胃肠病、内分泌、内科与初级保健)匿名迭代投票,共识预设为≥70%同意。
主要发现
- MASLD伴显著纤维化(≥F2)患者不良结局风险增加。
关键数值与推荐
- 风险分层从FIB-4起始,随后以振动控制瞬时弹性成像或ELF进行二次分层。
- 非肝硬化MASLD且LSM 10-20 kPa或ELF 9.2-11.3,排除肝硬化后可考虑resmetirom或semaglutide。
- 不推荐resmetirom与semaglutide upfront联合治疗。
- 药物选择应通过医患共同决策并根据患者心脏代谢特征个体化。
- 1年治疗应答定义为LSM下降≥30%或ELF下降≥0.5分。
临床怎么用
- 临床可按FIB-4→VCTE或ELF序贯路径评估纤维化风险。
- 对符合LSM 10-20 kPa或ELF 9.2-11.3的非肝硬化患者,结合心脏代谢特征共同决策选择resmetirom或semaglutide。
- 治疗1年按LSM降≥30%或ELF降≥0.5分评估应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have increased in prevalence alongside the global epidemics of obesity and type 2 diabetes and now represent one of the leading causes of chronic liver disease. Patients with MASLD and significant fibrosis (≥F2) are at increased risk for adverse outcomes. With advances in noninvasive tests (NITs) and the recent approval of resmetirom and semaglutide for noncirrhotic MASH with F2-F3 fibrosis, we provide updated consensus guidance on standardized risk stratification, treatment initiation, and response monitoring. METHODS: A structured Delphi process was conducted following a systematic updated literature review (January 2025-November 2025), covering the period since publication of the initial consensus recommendations, and included iterative anonymous voting among 40 international experts representing hepatology, gastroenterology, endocrinology, internal medicine, and primary care. Consensus was predefined as ≥70% agreement. RESULTS: Forty-two statements were developed; 86% achieved consensus in the first round, and all remaining statements reached consensus after refinement and the second round. The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification. Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient's cardiometabolic profile. Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF. CONCLUSIONS: This updated international consensus provides practical algorithms that integrate most commonly used noninvasive testing with recently approved pharmacologic therapies for MASLD, addressing current variability in clinical practice and supporting standardized implementation of risk-based care.
引用
- Younossi ZM, Kalligeros M, Wong VW, et al. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 41950980. doi:10.1016/j.cgh.2026.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。